Hepatoblastoma

Doctors + Care Team

Susan K. Parsons, MD, MRP
Request Appointment for Susan K. Parsons, MD, MRP

Susan K. Parsons, MD, MRP

Accepting New Patients

Title(s): Founding Director, Reid R. Sacco Adolescent and Young Adult Program for Cancer and Hereditary Blood Diseases; Director, The Center for Health Solutions at the Institute for Clinical Research and Health Policy Studies; Professor, Tufts University School of Medicine
Department(s): Pediatrics, Cancer Center, Medicine, Pediatric Hematology/Oncology, Hematology/Oncology
Appt. Phone: 617-636-5168
Fax #: 617-636-6280

Pediatric bone marrow transplantation, long-term quality of life following transplantation, supportive medical and emotional care for patients and families

View Full Profile for Susan K. Parsons, MD, MRP

Research + Clinical Trials

Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

The Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) directly addresses the need for the next generation of clinical trials for hepatic malignancies, incorporating rational reductions in therapy that ameliorate both short and long-term side effects for patients with good prognoses while simultaneously optimizing curative potential with intensification and new agent integration to improve outcomes for those with poor prognoses. This trial is the first international cooperative liver tumors trial in which a consensus approach was established by investigators representing Children's Oncology Group (COG), Societe Internationale d'Oncologie Pediatrique - Epithelial Liver Tumor Study Group (SIOPEL) and the Japanese Children's Cancer Group (JCCG). The study builds on treatment strategies established by the most recent trials from each of the individual consortia - COG (AHEP0731 ), SIOPEL (SIOPEL 3 and 4) and Japanese Pediatric Liver Tumor study group (JPLT2), but provides new approaches to all stages of HB and HCC patients keeping the aforementioned goals in focus. A critical aspect of this trial is the opportunity to correlate histologic and biologic heterogeneity with response and outcomes in all risk categories, providing promise for future refinement to the newly proposed risk stratification schema. 
More information about research and clinical trials